Vericel Corp
XMUN:ATQP
Vericel Corp
XMUN:ATQP
Price:
28.77
EUR
-1.32%
Market Closed
Market Cap:
€1.4B
Relative Value
The Relative Value of one
ATQP
stock under the Base Case scenario is
34.41
EUR.
Compared to the current market price of 28.77 EUR,
Vericel Corp
is
Undervalued by 16%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ATQP
Relative Value
Base Case
34.41
EUR
Undervaluation 16%
Multiples Across Competitors
ATQP Competitors Multiples
Vericel Corp Competitors
Vericel Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Vericel Corp
XMUN:ATQP
|
1.6B EUR | 5.9 | 99.4 | 66.7 | 136.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
388.4B USD | 6.4 | 92.8 | 15.3 | 21.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.4B USD | 5.4 | 25.6 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.9B USD | 6.1 | 21.2 | 13.2 | 16.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.2B USD | 9.9 | 30.2 | 22.7 | 23.7 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.8B USD | 5.5 | 17.5 | 12.9 | 14.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.1 | 34.5 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR | 10.6 | 34 | 36.8 | 37.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
